Roeten, M.S.F.; van Meerloo, J.; Kwidama, Z.J.; ter Huizen, G.; Segerink, W.H.; Zweegman, S.; Kaspers, G.J.L.; Jansen, G.; Cloos, J.
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. Cells 2021, 10, 665.
https://doi.org/10.3390/cells10030665
AMA Style
Roeten MSF, van Meerloo J, Kwidama ZJ, ter Huizen G, Segerink WH, Zweegman S, Kaspers GJL, Jansen G, Cloos J.
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. Cells. 2021; 10(3):665.
https://doi.org/10.3390/cells10030665
Chicago/Turabian Style
Roeten, Margot S.F., Johan van Meerloo, Zinia J. Kwidama, Giovanna ter Huizen, Wouter H. Segerink, Sonja Zweegman, Gertjan J.L. Kaspers, Gerrit Jansen, and Jacqueline Cloos.
2021. "Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells" Cells 10, no. 3: 665.
https://doi.org/10.3390/cells10030665
APA Style
Roeten, M. S. F., van Meerloo, J., Kwidama, Z. J., ter Huizen, G., Segerink, W. H., Zweegman, S., Kaspers, G. J. L., Jansen, G., & Cloos, J.
(2021). Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. Cells, 10(3), 665.
https://doi.org/10.3390/cells10030665